Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Black Diamond Therapeutics (BDTX) Operating Expenses (2018 - 2025)

Black Diamond Therapeutics (BDTX) has disclosed Operating Expenses for 3 consecutive years, with $26.1 million as the latest value for Q4 2021.

  • For the quarter ending Q4 2021, Operating Expenses rose 12.5% year-over-year to $26.1 million, compared with a TTM value of $126.9 million through Dec 2021, up 82.37%, and an annual FY2024 reading of $78.8 million, down 8.88% over the prior year.
  • Operating Expenses was $26.1 million for Q4 2021 at Black Diamond Therapeutics, down from $35.4 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $35.4 million in Q3 2021 and bottomed at $3.8 million in Q1 2019.
  • Average Operating Expenses over 3 years is $18.8 million, with a median of $16.8 million recorded in 2020.
  • The sharpest move saw Operating Expenses soared 235.3% in 2020, then grew 12.5% in 2021.
  • Year by year, Operating Expenses stood at $10.3 million in 2019, then soared by 124.12% to $23.2 million in 2020, then grew by 12.5% to $26.1 million in 2021.
  • Business Quant data shows Operating Expenses for BDTX at $26.1 million in Q4 2021, $35.4 million in Q3 2021, and $34.7 million in Q2 2021.